Skip to Content

Pfizer Inc PFE Stock Quote

| Rating as of

NYSE: PFE

Morningstar‘s Stock Analysis PFE

Valuation
Currency in USD
PFE is Fairly Valued at a 4% Premium.
PFE is 3 at a 4% 4.

1-Star Price

> 64.80

5-Star Price

< 33.60

Economic Moat

Wide

Trend: Stable

Capital Allocation

Standard

Pfizer Reports Solid Q3, Buoyed by Coronavirus Product Sales as Pipeline Investments Increase

Damien Conover Sector Director

Analyst Note

| Damien Conover |

Pfizer reported solid third-quarter results ahead of our expectations, but we don’t expect any major changes to our fair value estimate, as part of the strength stemmed from better-than-expected COVID-19 vaccine (Comirnaty) sales that will likely fade quickly in 2023. Nevertheless, the massive bolus of COVID-19-related sales (Comirnaty and COVID-19 treatment Paxlovid) generated almost $12 billion in the quarter, enabling Pfizer to redeploy capital toward the pipeline and acquisitions targeting innovative drugs (Biohaven and Global Blood Therapeutics), which should help support the firm’s wide moat. While we expect a major decline in COVID-19 sales due to the pandemic receding (even with the U.S. price increase on Comirnaty as the vaccine shifts to private payer markets from government pay), the recent increase in pipeline investments should help mitigate Pfizer’s expected patent headwinds that increase in 2028.

Excluding COVID-19 products, Pfizer’s sales increased 2% operationally, below our 5% sales growth projected over the next four years. Mixed performance of Pfizer’s leading products slightly weighed on the growth. The new Prevnar 20 launch in the U.S. is bolstering this entrenched franchise. Also, rare cardiovascular drug Vyndaqel continues to gain share with leading efficacy data. However, cancer drug Ibrance is struggling as competing drugs have show better efficacy data, setting up a flatter outlook.

On the pipeline front, Pfizer is making strides with two important launches in 2023. We are most bullish on the firm’s vaccine for respiratory syncytial virus as the data looks the most comprehensive in covering maternal and elderly patients. However, the competitive landscape is tough, with GSK’s competing RSV vaccine potentially showing slightly better efficacy, but the discontinuation of the GSK vaccine in the maternal setting could give Pfizer an edge. Also, strong data for ulcerative colitis drug etrasimod likely sets up another blockbuster.

Key Statistics PFE

Company Profile PFE

Business Description

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.

Contact
235 East 42nd Street
New York, NY, 10017
Industry Drug Manufacturers - General
Employees 79,000

Related Articles PFE

FAQs for Pfizer Inc Stock

Yes. PFE has a forward dividend yield of 3.22%. See PFE’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

PFE’s market cap is 282.49 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

PFE’s stock style is Large Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

PFE’s price/sales is 2.86.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

PFE’s price/forward earnings is 10.00.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

PFE’s price/book is 3.01.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See PFE’s valuation ratios compared to the Market Index.

PFE’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare PFE’s historical performance against its industry peers and the overall market.